In 511 participants with PD-L1 CPS ≥1 recurrent/metastatic head and neck SCC, adding lenvatinib to first-line pembrolizumab improved response (46.1% vs 25.4%) and median PFS (6.2 vs 2.8 months) at interim analysis, but not OS (HR 1.15); grade 3-4 AEs 66.9% vs 38.3%.
RCTn = 511
Licitra et al. Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study